SAADA‐BOUZID , Esmaa

BACKGROUNDPrognosis of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) remains poor. The addition of cetuximab, to platinum and fluorouracil chemotherapy (EXTREME regimen) has been shown to improve patients' outcomes in first-line settings.METHODSWe conducted a retrospective, multicenter study, including HNSCC that...